本報道最初發(fā)表于Endpoints News。請點擊這里查看原文
BioMarin plans to dish out $4.8 billion to acquire Amicus Therapeutics and its two approved rare disease medicines, the California biotech said Friday.
這家加州生物科技公司表示,BioMarin計劃斥資48億美元收購愛美醫(yī)療(Amicus Therapeutics)及其兩款已獲批的罕見病藥物。
您已閱讀5%(254字),剩余95%(5263字)包含更多重要信息,訂閱以繼續(xù)探索完整內(nèi)容,并享受更多專屬服務(wù)。